3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year


  • Biotech penny stocks are the clearest path to 10X gains over a 12 month period. 
  • eFFECTOR Therapeutics (EFTR): This small oncology company offers huge upside potential. 
  • Synlogic (SYBX): Addressing rare diseases is one way to provide 10X returns. 
  • Alzamend Neuro (ALZN): The neurological biopharma firm is a risky bet with big upside. 
penny stocks - 3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year

Source: Vitalii Vodolazskyi / Shutterstock.com

Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it’s not particularly likely to happen. Indeed, such an endeavor requires a penchant for risk and speculation. Additionally, investors may need to hone their efforts on particular high-growth sectors. One such group of penny stocks with 10x upside potential happens to be found in the biotech space.

Penny stocks in the biotech sector can certainly produce massive profits. Of course, these companies also carry very high risk. The question is whether the market believes, at a given point in time, whether said company’s potential products will hit the market. And if they do, what sort of market share such drugs could attain.

It’s a gamble.

That said, these three penny stocks in the biotech and Pharma space are worth considering.

EFTR eFFECTOR Therapeutics $0.54
SYBX Synlogic $0.53
ALZN Alzamend Neuro $0.53

eFFECTOR Therapeutics (EFTR)

OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock
Source: Gorodenkoff / Shutterstock.com

eFFECTOR Therapeutics (NASDAQ: EFTR) is certainly a prime example of the idea that pioneers in a specific niche can be worth a lot of money down the road. Building something novel and useful has led to riches over and over throughout history.

In the case of EFFECTOR Therapeutics, the company’s goal is to develop a new class of oncology drugs called selective translation regulator inhibitors (STRIs). This new class of drugs promises to inhibit the production of proteins that cancer cells utilize, thus preserving cell function.

eFFECTOR Therapeutics’ lead candidate, Tomivosertib, is currently in Phase 2b trials for treatment of non-small cell lung cancer. Another drug is being studied in Phase 1 and 2 clinical programs, while yet another is partnered with Pfizer (NYSE:PFE) in a study on solid tumors.

These are some very promising steps. However, investors in EFTR stock still need to rely on specific milestones being hit. That’s biopharma investing 101.

That which looks promising often never bears out. But when it does, 10X returns over the span of a year are entirely possible. This is the sort of risk/reward bet investors are making with eFFECTOR Therapeutics, as suggested by its consensus analyst target price.

Synlogic (SYBX)

Biochemical/biotech research scientist team working with microscope
Source: Mongkolchon Akesin / Shutterstock.com

Synlogic (NASDAQ:SYBX) is another biotech company, this time promising to treat diseases with high unmet need. It is a synthetic biology company focused on harnessing the power of artificial molecules and programmed genes to fight disease.

In particular, Synlogic is focused on creating a therapeutic for a disorder you may have heard of before – phenylketonuria. It’s a disorder in which patients cannot metabolize the amino acid phenylalanine. If that sounds familiar, it’s likely because diet soda often contains this amino acid. Warnings on the can may not always be heeded, but the reality is that phenylketonurics consumption can cause a rapid build-up in the blood called phenylketonuria, for certain patients.

Again, it’s a big guessing game as to whether SYBX skyrockets or not. Analysts appear to believe that such potential is possible, given the average consensus target price for SYBX stock right now. However, the fact that this company trades at around 54 cents per share at the time of writing highlights the risk of holding this stock right now.

Alzamend Neuro (ALZN)

PRTA stock alzheimer's disease with MRI.
Source: Atthapon Raksthaput / Shutterstock.com

Alzamend Neuro (NASDAQ:ALZN) is another stock trading below the 55 cent level I think is worth considering. Despite ALZN stock holding a current consensus price target of only $6.75, I think there’s the potential for much greater gains over the long-term.

That’s mostly because this company has promising candidates for both Alzheimer’s and Bipolar disorder, two key diseases with very important end markets.

For these key diseases, the company is proposing two lead candidate drugs, ALZ001 and ALZN002. AL001 is a patented combination of lithium, proline, and salicylate being studied for its potential to treat Alzheimer’s, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. ALZN002 might one day be used as a vaccine to restore patient immunological response to combat Alzheimer’s.

The company announced the initiation of Phase I/IIA trials of ALZN002 in treating mild to moderate Alzheimer’s dementia in early April. It takes cells from the patient and processes them outside the body to induce immunogenicity before reintroducing them into the patient’s body. If the company can commercialize that process with FDA approval, it will make a lot of money for investors.

Penny Stocks

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More: Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.

Article printed from InvestorPlace Media, https://investorplace.com/2023/05/3-penny-stocks-that-could-turn-1000-into-10000-in-a-year/.

©2023 InvestorPlace Media, LLC